Aditxt Inc. (ADTX) announced a new capitalization strategy that combines bitcoin reserves with equity funding to support its biotech commercialization efforts. The company’s board of directors approved the bitcoin-backed treasury strategy as part of its "bitXbio" plan.

The Mountain View, California-based company plans to establish a bitcoin reserve, subject to fund availability, alongside its existing equity line facility. Aditxt has approximately $125 million available under its common stock purchase agreement, with the ability to sell up to 50 million shares under its registration statement declared effective by the SEC on June 30, 2025.

The strategy aims to support planned monetization events beginning in 2026, including a potential initial public offering for Pearsanta, one of Aditxt’s portfolio companies. The company operates as a social innovation platform focused on autoimmunity and early disease detection programs.

"bitXbio is a forward-looking strategy designed to align our capital structure with the value-creation potential of our biotech pipeline," said Amro Albanna, co-founder and CEO of Aditxt. "As we look to strengthen our balance sheet and enterprise value, we plan to seek to integrate digital currency reserves, subject to the availability of funds."

Aditxt is also working toward acquiring Evofem under a July 2024 merger agreement, with a targeted close in the second half of 2025. The transaction requires approximately $17 million in cash payments and is subject to several conditions including shareholder approval and capital raising requirements.

The company’s business model focuses on acquiring, building, and capitalizing health and biotechnology ventures through its innovation platform.